Search Intelligence

“Targeting shared neoantigens with an off-the-shelf viral vector avoids the per-patient manufacturing bottleneck of individualized cancer vaccines, though registration-enabling trials will have to prove that a 43-patient Phase 1b/2 signal holds up at scale.”